Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis

BACKGROUND/AIMS: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no head-to-head comparison of treatment efficacy and outcomes between the two agents. The aim of this study was to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong Il, Park, Yehyun, Park, Soo Jung, Kim, Tae Il, Kim, Won Ho, Cheon, Jae Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960969/
https://www.ncbi.nlm.nih.gov/pubmed/32616683
http://dx.doi.org/10.5009/gnl19433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960969/
https://www.ncbi.nlm.nih.gov/pubmed/32616683
http://dx.doi.org/10.5009/gnl19433

Ejemplares similares